The current gold standard for measuring and tracking brain health is not only hugely expensive, but time-consuming, invasive and cumbersome for the patient, and not as accurate as it could be. Aura Analytics is a health tech company that’s providing a new, inexpensive, and highly accurate method for early detection and longitudinal tracking in brain health, which encompasses Alzheimer’s disease, Parkinson’s disease, ALS, and other disorders affecting fine motor and cognitive function.
CEO and co-founder of Aura Analytics, Daniel Jones, explains how their product works: patients complete a simple, three to five minute set of tasks on a mobile device app that asks specific questions targeting task-specific areas of the brain. The tasks solicit a speech sample from the patient, which is immediately sent to the cloud and subjected to a series of machine learning algorithms that generate and deliver to clinicians in real time objective, finite results.
Built on 25 years worth of data from the National Science Foundation and National Institutes of Health, the Aura Analytics technology has shown a level of accuracy in the 90th percentile of all currently used methods of measuring brain health. Patient feedback has already been overwhelmingly positive, and Aura Analytics is now partnering with major pharmaceutical companies and health systems to carry out large-scale clinical trials and gain more widespread acceptance.
Daniel Jones expects their first major breakthrough with the FDA to happen in about 18 months, and in the meantime, his efforts are focused on gaining external validation and eventual clinician and consumer adoption. Tune in for the full discussion, and visit auralanalytics.com to learn more.